OLMA Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
58.0M
+15.8%
50.1M
+9.2%
45.9M
-4.2%
47.9M
+37.3%
34.9M
R&D
49.2M
+13.9%
43.2M
+8.2%
40.0M
-9.0%
43.9M
+43.4%
30.6M
SG&A
8.8M
+27.5%
6.9M
+15.8%
5.9M
+49.6%
4.0M
-6.8%
4.2M
Operating Income
-57986000
-15.8%
-50084000
-9.2%
-45877000
+4.2%
-47864000
-37.3%
-34873000
EBITDA
-57867000
-16.0%
-49897000
-8.9%
-45834000
+4.0%
-47732000
-37.4%
-34745000
Net Income
-53089000
-15.3%
-46061000
-9.1%
-42217000
+3.6%
-43784000
-44.1%
-30389000
EPS (Basic)
$-0.52
-4.0%
$-0.50
-2.0%
$-0.49
+3.9%
$-0.51
-41.7%
$-0.36
EPS (Diluted)
$-0.52
-4.0%
$-0.50
-2.0%
$-0.49
+3.9%
$-0.51
-41.7%
$-0.36
Shares (Diluted)
102.8M
+12.5%
91.4M
+6.6%
85.7M
+0.3%
85.5M
+0.1%
85.4M
Olema Pharmaceuticals (OLMA) โ€” Financials